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Actinobacteria from Antarctica 
as a source for anticancer discovery
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Although many advances have been achieved to treat aggressive tumours, cancer remains a 
leading cause of death and a public health problem worldwide. Among the main approaches for the 
discovery of new bioactive agents, the prospect of microbial secondary metabolites represents an 
effective source for the development of drug leads. In this study, we investigated the actinobacterial 
diversity associated with an endemic Antarctic species, Deschampsia antarctica, by integrated 
culture‑dependent and culture‑independent methods and acknowledged this niche as a reservoir 
of bioactive strains for the production of antitumour compounds. The 16S rRNA-based analysis 
showed the predominance of the Actinomycetales order, a well‑known group of bioactive metabolite 
producers belonging to the Actinobacteria phylum. Cultivation techniques were applied, and 72 
psychrotolerant Actinobacteria strains belonging to the genera Actinoplanes, Arthrobacter, Kribbella, 
Mycobacterium, Nocardia, Pilimelia, Pseudarthrobacter, Rhodococcus, Streptacidiphilus, Streptomyces 
and Tsukamurella were identified. The secondary metabolites were screened, and 17 isolates were 
identified as promising antitumour compound producers. However, the bio-guided assay showed 
a pronounced antiproliferative activity for the crude extracts of Streptomyces sp. CMAA 1527 and 
Streptomyces sp. CMAA 1653. The TGI and  LC50 values revealed the potential of these natural products 
to control the proliferation of breast (MCF-7), glioblastoma (U251), lung/non-small (NCI-H460) 
and kidney (786-0) human cancer cell lines. Cinerubin B and actinomycin V were the predominant 
compounds identified in Streptomyces sp. CMAA 1527 and Streptomyces sp. CMAA 1653, respectively. 
our results suggest that the rhizosphere of D. antarctica represents a prominent reservoir of bioactive 
actinobacteria strains and reveals it as an important environment for potential antitumour agents.
In general, microbial natural products have higher selectivity and bioactivity indices when compared to com-
binatorial chemistry  libraries1,2. The search for bioactive molecules from microorganisms has received growing 
attention in recent  decades3–5. Part of this is due to the specific action of microbial metabolites as substrates for 
many transport systems, which allows the release of compounds into intracellular  sites6,7. However, despite the 
extensive search for microbial metabolites to address a great deal of clinical threat, the discovery rate of new and 
effective drug compounds has been declining every year, which is due, in part, to the use of traditional techniques 
of chemical isolation and the investigation of microorganisms in extensively studied  environments3,8,9.
Thus, bioprospecting studies have advanced into auspicious ecological niches, which tend to favour the 
prevalence of exotic metabolisms and endemic  species10,11. In this context, the Antarctic continent has been 
considered one of the most promising bioprospecting ecosystems and a valuable source to isolate new and diverse 
microorganisms due to its environmental peculiarities, such as extremely low temperatures and precipitation, 
high levels of UV radiation, ocean flooding, high salinity rates, and large unexplored  areas12–16.
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Although many organisms are adapted to the harshest environmental conditions of the Antarctic, the spe-
cies Deschampsia antarctica Desv. (Poaceae) and Colobanthus quitensis (Kunth) Bartl. (Caryophyllaceae) have 
received more attention because they represent unique vascular plants in the whole Antarctic continent and play 
an important ecological role as a shelter for a plethora of microbes with wide metabolic  capacities17,18. However, 
the reduced dispersion of D. antarctica Desv. in few Antarctic sites has attracted special interest in ecological 
and bioprospecting  investigations17,19,20.
In this way, several studies have been carried out to characterize the microbiome associated with Antarctic 
hairgrass (D. antarctica), as well as to understand the adaptive mechanisms of this species to survive the harsh 
environmental conditions of  Antarctica21–23. Even so, studies exploring the potential of this microbiome to access 
novel cultivable strains and bioactive compounds are still scarce.
Recently, Sivalingam and colleagues (2019)24 reported the prominence of Actinobacteria, especially species 
of Streptomyces, derived from extreme sources as an extraordinary reservoir of novel biosynthetic gene clusters 
with potential for developing anticancer drugs. Indeed, actinomycetes have been recognized as a prolific source 
of natural products with a myriad of bioactivities, including phytotoxic, antimicrobial, insecticidal and mainly 
antiproliferative and antitumour  activities25–28. Compound classes belonging to the peptides, polyketides, mac-
rolides, quinolones and others represent these  bioactivities28–32. Accordingly, the isolation and identification of 
actinomycetes have become a fruitful area of research in recent years that has subsequently led to the identifica-
tion of novel Actinomycete species that should be exploited to unveil possible biosynthetic pathways and discover 
new bioactive natural  products12,33–35. Thus, the rhizosphere bacterial composition of Antarctic hairgrass (Fig. 1) 
was investigated by the 16S rRNA gene sequencing and the cultivable associated actinobacteria were evaluated 
as potential sources of antitumour compounds.
Results
Bacterial community associated with Deschampsia antarctica rhizosphere. In this study, a total 
of 249.176 high-quality 16S rRNA reads were recovered after the QC filter step (Table S1—Supplementary Mate-
rial). Sequences were assigned to 229.631 OTUs, and the rarefaction curves reached the plateau phases, confirm-
ing the adequate sequencing depth of the samples. The bacterial community structure revealed by the higher-
ranking taxa classification was congruent among the different rhizosphere samples (Fig. 2).
The average taxonomic signatures of all samples from sites Morro da Cruz, Torre Meteoro Direito e Torre 
Meteoro Esquerdo (MDC, TMD and TME, respectively) showed that Actinobacteria (34%) was the most abun-
dant phylum, followed by Chloroflexi (21%) and Proteobacteria (20%) (Fig. 2a). Members of the phyla Acidobac-
teria and Verrucomicrobia were detected at lower frequencies (< 5%). The ‘unclassified’ sequences contributed 
to 7% of the dataset, showing that the understanding of the plant-microbiome interaction is still limited and 
Figure 1.  Satellite images (Google Earth Pro, 2019) and study sites. (A) Antarctic Continent; (B) Antarctic 
Peninsula; (C) South Shetland Islands; D-E–F) King George Island [sampling sites: Torre Meteoro Direito—
TMD, Torre Meteoro Esquerdo—TME and Morro da Cruz—MDC (green, red and yellow location icon, 
respectively)]; (G) Deschampsia antarctica Desv.
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that the rhizosphere of D. antarctica may harbour unknown taxonomic groups to be further explored. A more 
detailed taxonomic analysis showed that the phylum Actinobacteria was mainly represented by members of 
the order Actinomycetales (86%), followed by Acidimicrobiales (8%) and Solirubrobacteriales (3%) (Fig. 2b).
functional prediction of the bacterial communities. The predictive functional profile of the entire 
rhizosphere-associated bacterial community resulted in more than 6,500 protein-coding genes, which could be 
assigned to 329 KEGG Orthology functional categories (KOs). To determine a specific functional contribution, 
Actinobacteria-affiliated 16S rRNA reads were extracted and compared with the predictive functional traits of 
the total bacterial community. Principal component analysis (PCA) showed a clear separation between the pre-
dicted functional profiles of the total bacterial community and Actinobacteria groups (Figure S1—Supplemen-
tary Material). Nineteen KOs were significantly over-represented (p-value < 0.05) between the two datasets. The 
pathways carbohydrate metabolism, amino acid metabolism, metabolism of terpenoids and polyketides, xeno-
Figure 2.  Taxonomic composition of Deschampsia antarctica rhizosphere collected across three sites revealed 
by 16S rRNA marker sequencing. (A) Bacteria phylum; (B) Order-level taxonomic affiliation of OTUs filtered 
from Actinobacteria phylum (Caporaso et al., 2011; Caporaso et al., 2010)36,37.
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biotic biodegradation and metabolism, DNA replication and repair, membrane transporter, and biosynthesis of 
other secondary metabolites were significantly enriched (p < 0.05) in the Actinobacteria dataset when compared 
to the total bacterial community (Fig. 3).
isolating, culturing and identifying actinobacteria. A total of 72 actinomycetes were isolated with 
the media and procedures employed in this study. The isolates belonged to the genera Actinoplanes, Arthrobac-
ter, Kribbella, Mycobacterium, Nocardia, Pilimelia, Pseudarthrobacter, Rhodococcus, Streptacidiphilus, Strepto-
myces and Tsukamurella from 6 families in the phylum Actinobacteria. Genomic analysis based on 16S rRNA 
sequences was used to select 30 isolates as representative strains of the accessed actinomycetes diversity. The 
nearest type strains, the percentage of identity and the GenBank access number are presented in Table S2—Sup-
plementary Material. The strains are deposited in the Collection of Microorganisms of Agricultural and Envi-
ronment Importance (CMAA)—Embrapa, Brazil (Fig. 4).
Screening for bioactive strains. First, all thirty isolated strains were evaluated against Pythium aphani-
dermatum CMAA  243T. Seventeen strains showed growth inhibition effects, as determined by the antagonism 
test (Figure S2 and Table S3—Supplementary Material), and these strains were selected for the antiproliferative 
assay against human tumour cell lines; glioma (U251), breast 174 (MCF-7) and lung/non-small cells (NCI-
H460). Two strains, CMAA 1527 and CMAA 1653, exhibited potent activity, considering that Total Growth 
Inhibition (TGI) values lower than 6.25 µg/mL. Crude extracts of both CMAA 1527 and CMAA 1653 com-
pletely inhibited the growth of breast (MCF-7, TGI < 0.25 µg/mL, both extracts), glioblastoma (U251, TGI = 3.05 
and < 0.25 µg/mL, respectively) and non-small lung (NCI-H460, TGI = 0.57 and 5.8 µg/mL, respectively) tumour 
cells (Fig. 5).
phylogenetic analysis. According to the phylogenetic reconstruction based on the 16S rRNA gene simi-
larity the bioactive actinobacterial strains were affiliated with the genus Streptomyces. The CMAA 1527 strain 
was closely related to Streptomyces aurantiacus NBRC  13017T, while CMAA 1653 was related to Streptomyces 
fildesensis DSM  41987T (Fig. 6), although they form a distinct phyletic branch towards the phylogenetic tree.
Bioassay-guided fractionation and structural identification of compounds. The crude extracts 
obtained from Streptomyces sp. CMAA 1527 and Streptomyces sp. CMAA 1653 showed high antiproliferative 
activity. Both extracts were analysed by LC–MS and presented different chemical profiles (Fig. 7).
The major peak in Streptomyces sp. CMAA 1527 crude extract was analysed by LC–MS at the retention time 
of 13.15 min and had mass spectra with m/z 826 (Fig. 7a). The extract was fractionated by semi-preparative 
HPLC, resulting in 4 grouped fractions (FR-1, FR-2, FR-3 and FR-4) that were subjected to a biological assay. 
Figure 3.  Extended error bar plot showing the predicted KO-level 2 categories significantly different between 
total community and Actinobacteria members from Deschampsia antarctica Desv. rhizosphere (n = 9). Only 
P < 0.05 is displayed. (Kanehisa; Goto, 2000; Kanehisa et al., 2019; Kanehisa, 2019; Langille et al., 2013)38–41.
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Figure 5c and Table 1 shows the antiproliferative potential of fraction FR-3, the most bioactive fraction accord-
ing to human cancer cell line panel. FR-3 was submitted to structural identification experiments, although other 
fractions showed lower biological activities (data not shown).
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The chemical structure of FR-3 was confirmed by the analysis of the HRESIMS spectrum, and the molecu-
lar formula was determined to be  C42H51NO16 as [M + H]+ was observed at m/z 826.3298 u, calculated for 
 C42H52NO16+ (Figure S3—Supplementary Material). Cinerubin B was identified based on spectral data such as 
HRESIMS, 1H NMR, COSY, gHMBC, and gHMQC. The compound was isolated as a red amorphous powder that 
was soluble in methanol (MeOH) and trichloromethane  (CHCl3) with UV absorption maxima at 490 nm. The 
1H NMR spectrum of cinerubin B (Figure S4—Supplementary Material) showed signs of characteristic chemi-
cal shifts of anthracycline class; the signals of phenolic hydrogen were at δ 12.99 (s, 1H), δ 12.83 (s, 1H), and 
δ 12.28 (s, 1H). There were also signs of aromatic hydrogen at δ 7.75 (s, 1H) and δ 7.33 (d, J = 4.41 Hz, 2 H), as 
well as a broad doublet for a carbinolic hydrogen at δ 5.27 (dl, J = 2.50 Hz, 1 H). Other observed signals that are 
characteristic of this compound refer to three methoxyl group hydrogens at δ 3.71 (s, 3H), the hydrogen signals 
from an ethyl group at δ 1.76 (q, J = 7.0 Hz, 2H) and δ 1.09 (t, J = 7.0 Hz, 3H), and the methyl hydrogen signals 
belonging to an N-dimethyl group at δ 2.16 (s, 6H). In addition, the presence of three anomeric hydrogens at δ 
5.49 (sl, 1H), δ 5.12 (dl, J = 2.9 Hz, 1H), and δ 5.21 (dl, J = 2.9 Hz, 1H) indicated the presence of a trisaccharide 
moiety in the chemical structure of the compound. The 2D correlations from the HMBC and COSY spectra 
(Table S4—Supplementary Material) were used to assign all signals present in the cinerubin B structure (Fig. 8 
and Figure S5—Supplementary Material).
In order to identify other anthracyclines the LC–MS/MS analysis using neutral loss methodology was per-
formed. The chemical structure of the predominant compound produced by Streptomyces sp. CMAA 1527 
(cinerubin B; m/z 826.3298 u) showed a neutral loss of 240 u, which refers to a charge-remote hydrogen rear-
rangement with consequent loss of disaccharide cinerulosyl-2-deoxyfucosyl to form the product ion m/z 586 as 
a base peak, which it was attributed to pyrromycin. This methodology allowed us to show the presence of other 
bioactive compounds in the crude extract (Figure S6—Supplementary Material) but with lower concentrations 
than cinerubin B since it was not possible to perform the isolation process. These compounds were identified 
as 1 or 11-hydroxysulfurmycin B (m/z 854), auramycin B (m/z 812) or N-desmethylcinerubine B (m/z 812) and 
1-deoxycinerubin B (m/z 810) which have been attributed to the lower bioactivities detected at the others frac-
tions (Figure S7, S8 and S9, respectively—Supplementary Material). Furthermore, it is noteworthy that these 
Figure 5.  Antiproliferative activity in tumor cell lines. (A) Streptomyces sp. CMAA 1527 crude extract; (B) 
Streptomyces sp. CMAA 1653 crude extract; (C) Fraction FR-3 (produced by Streptomyces sp. CMAA 1527) and 
(D) Fraction FR-7 (produced by Streptomyces sp. 1653).
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metabolites have isomeric structures; therefore, for unambiguous confirmation, it is necessary to perform NMR 
spectroscopic characterization for each of the isolated metabolites.
The analysis of the Streptomyces sp. CMAA 1653 crude extract revealed a predominant peak at 25.30 min 
corresponding to mass spectra m/z 1,269 (Fig. 7b and Figure S10—Supplementary Material). The HRESIMS/
MS spectrum showed the main product ions of m/z 956, m/z 857, m/z 657, m/z 558, m/z 459, m/z 399, and m/z 
300 (Figure S11—Supplementary Material). These ions provided abundant structural information, and their 
identification was performed. HRESIMS/MS data were identical to those previously reported in the  literature44. 
As a result of the fractionation procedures, FR-5, FR-6 and FR-7 were recovered, within the FR-7 portion as the 
main bioactive fraction (Fig. 5d and Table 1). Thus, the compound present in the fraction FR-7 was identified as 
actinomycin V  (C62H84N12O17) (Fig. 9). The other fractions obtained by semi-preparative HPLC did not show 
bioactivity in the experiments carried out in this study.
Discussion
The analysis of the rhizosphere microbiota in cold extreme habitats is crucial to understand the ecological roles 
and unlocking the biotechnological potential of these environments. Actinobacteria was also the dominant 
phylum in the rhizosphere of other D. antarctica retrieved from the maritime Antarctica region, as well as soils 
from cold and desert  environments45–48. This prevalence may be explained by their spore-forming ability, UV 
radiation tolerance and other environmental adaptations that ensure survival in harsh conditions. Actinobacterial 
genera are known for their great potential to produce several bioactive  substances47,49,50, although they also have 
the ability to degrade and use complex organic compounds and for their bioremediation of contaminated  soils51. 
In fact, the predictive functional analysis using the Actinobacteria-derived 16S rRNA gene sequences showed 
Figure 6.  Phylogenetic tree based on the 16S rRNA gene sequences, obtained by Neighbor–Joining method 
analysis for the bioactive strains CMAA 1527 and CMAA 1653 and their closely related type strains—MEGA 
7.042. Numbers at nodes indicate the level of bootstrap support based on 1,000 replications (only values > 50% 
are shown). Streptacidiphilus oryzae was used as outgroup for this study.
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enrichment of some functional categories related to carbohydrate metabolism, xenobiotic biodegradation and 
bioactive compound biosynthesis when compared with the total bacterial community. Vikram et al. (2016)52 
also showed the genetic potential of Actinobacteria for C metabolism and membrane transport systems, which 
supports our PICRUSt functional predictions. The results obtained by 16S rRNA gene sequencing coupled to 
predictive functional analysis were useful to reveal diversified Actinobacteria pathways to produce biologically 
active metabolites. In doing so, we reported the presence of many pathways related to the biosynthesis of antibiot-
ics such as streptomycin, novobiocin, phenylpropanoids, pyridine alkaloids, stilbenoids, neomycin, vancomycin, 
and tetracyclines, indicating a great bioactive potential of the bacterial community associated with D. antarctica 
(Table S5—Supplementary Material).
Despite advances in environmental sequencing (metagenomics) and single-cell genomics, the screening 
procedures of novel molecules remain largely related to the microorganisms  culturing53. Thus, efforts to isolate 
new psychrotolerant strains were performed, resulting in a diverse collection of Actinobacteria revealed by the 
16S rRNA gene sequencing. However, recent studies have found that discrepancies in terms of chemical and 
morphological features were possible in microorganisms belonging to same taxonomy, as determined for identical 
16S rRNA gene  sequences54. This finding was especially observed when studying bacteria from geographically 
distant origins or associated with different host species, in accordance to the ecovar  concept55–57. Therefore, 
although the limitations of 16S rRNA gene have been widely recognized for screening of bioactive strains, we 
have assumed that the rhizosphere of D. antarctica could lead to high grade of specialism, with a lot of clonal 
populations. This fact was also observed in the 16S rRNA sequences of all isolated strains (data not shown), and 
supported by previous reports of Antarctic microbiota, which demonstrated that the type of habitat dramatically 
constrained the bacterial community  composition45,58.
Although the Actinobacteria diversity has been underestimated through cultivation-dependent tech-
niques, the isolation was able to access undiscovered species with the potential to produce novel bioactive 
 compounds59–61. Some of them were not detected in microbiome analysis, possibly belonging to the rare com-
munity. Indeed, previous studies reported that cultivation techniques are still unable to access the real microbial 
diversity found in natural environments. The cultivation of recalcitrant microorganisms from extreme environ-
ments is difficult, especially the rhizosphere of Antarctic plants. However, the use of different culture media and 
growing conditions may be tested to improve the recovery of a major diversity of Actinobacteria  members14,62. 
The low sequence identity registered in this study indicates the potential to identify novel species that require a 
polyphasic taxonomic approach for proper characterization and description. Based on phylogenetic, phenotypic 
Figure 7.  Chromatogram TIC obtained by LC–MS of crude extracts: (A) Streptomyces sp. CMAA 1527 and (B) 
Streptomyces sp. CMAA 1653.
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and chemotaxonomic data, a new actinobacterial species isolated from D. antarctica was recently identified, 
named Rhodococcus psychrotolerans sp.  nov12.
For current purposes, antiproliferative screening using P. aphanidermatum CMAA  243T as a model organ-
ism resulted in 17 bioactive strains. The bioassay was followed the protocol successfully applied to the primary 
screening against the Oomycota Pythium, which contain in its hyphal walls and cell membrane, proteins, lipids 
Table 1.  In vitro antiproliferative activity of crude extracts and bioactive fractions against human tumor and 
non-tumor cell lines. (a) Doxorubicin: chemotherapeutic drug; (b) TGI: Total Growth Inhibition (sample 
concentration required for total cell growth inhibition) and (c)  LC50: Lethal Concentration 50 (sample 
concentration required to elicit 50% of cell death), expressed in µg/ml followed by standard error, calculated 
by sigmoidal regression using Origin 8.0 software. Results classified according to NCI’s criteria based on 
TGI values (I, inactive sample: TGI > 50 μg/ml; W, weak activity: 15 μg/ml < TGI < 50 μg/ml; M, moderate 
activity: 6.25 μg/ml < TGI < 15 μg/ml; P, potent activity: TGI < 6.25 μg/ml)43.  LC50 results were compared by 
Test t-student [#: statistically significant difference (p ≤ 0.05) between fractions FR-3 and FR-7 in the same cell 
line]. Human tumor cell lines: 1 = U251 (glioblastoma); 2 = MCF-7 (breast, adenocarcinoma); 3 = NCI/ADR-
RES (ovary, multi-drug resistant adenocarcinoma), 4 = 786–0 (kidney, adenocarcinoma), 5 = NCI-H460 (lung, 
large cell carcinoma); 6 = OVCAR-3 (ovary, adenocarcinoma), 7 = HT-29 (colon, adenocarcinoma), 8 = K-562 
(chronic myeloid leukemia); Human non tumor cell line: 9 = HaCaT (immortalized keratinocyte); (*) effective 
concentration (TGI or  GI50) > 250 μg/mL; (* *) effective concentration (TGI or  GI50) < 0.25 μg/mL; (ND) not 
determined.
Cell lines
Crude extracts and bioactive 
fractions 1 2 3 4 5 6 7 8 9
TGI (μg/ml)b
Doxorubicina 0.56 ± 0.42 (P) 0.42 ± 0.11 (P) 2.3 ± 0.9 (P) 4.2 ± 4.3 (P) * *(P) 1.3 ± 0.4 (P) 3.6 ± 1.8 (P) 2.4 ± 0.8 (P) 0.16 ± 0.04 (P)
CMAA 1527 3.05 ± 0.09 (P) * * (P) ND ND 0.57 ± 0.67 (P) ND ND ND * * (P)
CMAA 1653 * * (P) * * (P) ND ND 5.8 ± 3.3 (P) ND ND ND 0.31 ± 0.03 (P)
Fraction FR-3 0.65 ± 0.43 (P) 5.7 ± 5.7 (P) * * (P) 3.2 ± 4.2 (P) 1.5 ± 2.6 (P) * * (P) * * (P) * * (P) * * (P)
Fraction FR-7 0.31 ± 0.11 (P) 1.4 ± 2.3 (P) * * (P) 1.5 ± 1.3 (P) 0.51 ± 0.27 (P) * * (P) * * (P) * * (P) * *(P)
LC50 (μg/ml)c
Doxorubicina  > 25  > 25  > 25  > 25  > 25  > 25  > 25 25 1.7 ± 1.6
Fraction FR-3 38.8 ± 31.6 * * * * * 54.1 ± 33.4 11.2 ± 6.7 0.51 ± 0.54





















































Figure 8.  The main HMBC and COSY correlations observed for cinerubin B.
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and sterols such as cholesterol, compounds which resemble cancer cells. The advantage of this method is the 
simplicity, low cost and  practicality63. Among these strains, Streptomyces sp. CMAA 1527 and Streptomyces 
sp. CMAA 1653 stood out, showing a high antiproliferative index for human tumour cells. According to the 
phylogenetic reconstruction and 16S rRNA gene similarity, Streptomyces sp. CMAA 1527 was closely related to 
Streptomyces aurantiacus NBRC  13017T (99.37%), while Streptomyces sp. CMAA 1653 was related to Streptomyces 
fildesensis DSM  41987T (99.72%). Interestingly, Streptomyces fildesensis DSM  41987T was isolated from Antarctic 
soil and was recently presented as a prominent producer of antibiotic  compounds64. Although both strains have 
been presented in the literature, they have not been listed as potential producers of antitumour compounds.
Cinerubin B is an important compound belonging to the anthracycline class. Anthracyclines are a special class 
of antibiotics widely used as antitumour agents, and the compounds daunomycin, doxorubicin, adriamycin, and 
aranciamycin anhydride have received great attention since their  discovery65. The pronounced activity presented 
in the secondary metabolites of Streptomyces sp. CMAA 1653 can be clearly justified by the presence of actino-
mycin V (m/z 1,269.6170 u). The product ions at m/z 956, m/z 857, m/z 657, m/z 399 and m/z 300 corresponded 
to the loss of the Val-Pro-Sar-MeVal chain and were similar to those observed for actinomycin  D44. Moreover, 
the product ion at m/z 558 indicated the presence of another Pro-Sar-MeVal residue in structure, as well as the 
product ion at m/z 459, which was characteristic of the core nucleus structure of  actinomycins44,66. Actinomycins 
have been used as chemotherapeutic agents for the treatment of a variety of cancers and are produced by many 
Streptomyces  strains24. They are a family of bicyclic chromopeptide lactones that attach two pentapeptide lactones 
of nonribosomal origin. Its use dates approximately 70 years ago, acting under several types of malignant human 
tumours, including nephroblastoma (Wilms’ tumour) and childhood  rhabdomyosarcoma67–69, and has attracted 
attention for its potential to assist in the development growth of multi-drug resistance strains and inhibition of 
HIV-1 reverse  transcriptase44,70,71.
conclusions
This study reveals that the root-associated bacteria of Deschampsia antarctica Desv. from Antarctic ecosystems are 
a rich source of molecules with antitumour properties. The isolation methods employed in this study were able 
to retrieve Actinobacteria taxa that were not detected in microbiome analysis, showing that the combination of 
both strategies may be useful for recovering both rare and abundant members of the Actinobacteria communities 
for biotechnological exploration. The secondary metabolites of Streptomyces sp. CMAA 1527 and Streptomyces 
sp. CMAA 1653 showed valuable antiproliferative activities against human cancer cells and therefore can con-
tribute significantly to the development of drugs of technological importance. Cinerubin B and actinomycin 
V were identified in the bioactive fractions of Streptomyces sp. CMAA 1527 and Streptomyces sp. CMAA 1653, 
respectively, but many other potential bioactive compounds can still be explored from Antarctic Actinobacteria. 
Based on these results, one of the two native Antarctic plants represents an attractive and unique model for the 
study of symbiosis and the discovery of antitumour lead compounds by the associated microbiome.
Methods
Sampling sites. Rhizospheric soil samples were collected (early summer Nov. 2014) at three different points 
(Morro da Cruz—62°05′04.3″ S/58°23′41.7″ W; Torre Meteoro Direito—62°05′10.4″ S/58°23′34.6″ W and Torre 
Meteoro Esquerdo—62°05′08.1″ S/58°23′36.6″ W) in Admiralty Bay, King George Island, South Shetland Islands, 
Antarctica. Deschampsia antarctica rhizospheric soil was obtained by removing plants from the soil (three plants 
Figure 9.  Chemical structure of actinomycin V.
11
Vol.:(0123456789)
Scientific RepoRtS |        (2020) 10:13870  | https://doi.org/10.1038/s41598-020-69786-2
www.nature.com/scientificreports/
for each collection point) and scraping 1–2 mm of soil adhering to the roots. Samples intended to actinobacteria 
isolation were kept at 4 °C and samples selected to genomic approach was stored at -20 °C until processed.
Bacterial 16S rRNA metabarcoding sequencing. DNA extractions of the rhizosphere samples were 
performed using the PowerSoil DNA Isolation Kit (MoBio Laboratories—Carlsbad, CA, USA), according to the 
manufacturer’s instructions. DNA yield and purity was evaluated by Qubit Fluorometric Quantification (Life 
Technologies—San Diego, CA, USA) and NanoDrop spectrophotometer (ThermoFischer Scientific—Waltham, 
MA, USA) (checking by the A260nm/280 nm and A260nm/230 nm ratios). The total DNA extracted from rhizo-
sphere samples was ordered to the massive sequencing of the 16S rDNA gene for bacterial diversity analysis. The 
amplicons were obtained by the amplification of V6 16S rRNA hypervariable  region72, using the primers 967F 
(5′-CAA CGC GAA GAA CCT TAC C-3′) e 1193R (5′-CGT CRT CCC CRC CTTCC-3′)73, with an additional tag of 
five nucleotides added for each sample (https ://vamps .mbl.edu/), according to Souza et al. (2017)74. The PCR 
products were pooled in equimolar ratio and purified by the SizeSelect EX E-Gel electrophoresis system (Life 
Technologies Corporation) for DNA size selection. The recovered fragments were further purified using the 
Agencourt AMPure XP kit (Beckman Coulter—Brea, CA, USA). Purified library product was quantified using 
the Qubit Fluorometric Quantification. The emulsion PCR procedure and sample enrichment were performed 
on the Ion OneTouch 2 system using the Ion Template PGM OT2 400 kit (Life Technologies Corporation). 
The V2 316 chip was used for sequencing as instructed in the Ion Torrent platform manual (Personal Genome 
Machine—PGM, Life Technologies Corporation).
Statistical and bioinformatic analyses. Raw data obtained from Ion Torrent sequencing were converted 
to FASTA file and submitted to quality control (QC) using the Galaxy  platform75, with the following QC param-
eters: quality score = 25; barcode size = 5; quality window = 50, and maximum number of homopolymers = 6. 
Sequences with low quality and lengths < 180 bp were removed. After QC, the remaining high-quality reads were 
analyzed by the Quantitative Insights Into Microbial Ecology (QIIME) version 1.9 software  package36. Open 
reference operational taxonomic unit (OTU) were grouped at 97% sequence similarity OTU using UCLUST 
method and representative sequences of each OTU were taxonomically classified using the PyNAST alignment 
against GREENGENES (version gg_13_8) 16S reference  database37,76. Chimeric sequences were detected and 
removed by the UCHIME  algorithm76 before the construction of the OTU table. Afterward, all OTUs consisting 
of one single sequence (singletons), chloroplasts and non-bacterial sequences were removed before taxonomic 
classification.
The accurate predictive analysis was performed to infer the functional contribution of rhizosphere-associated 
Actinobacteria in comparison with the total community. Then, the PICRUSt  tool41 was used to predict KEEG 
Orthology (KO) functional profiles of the bacterial community using the 16S rRNA dataset based on OTUs and 
reference genomes  database38–40. For this, 16S reads affiliated to the Actinobacteria phylum were filtered after 
Greengenes database annotation. The final output of this workflow was quantified in terms of predicted func-
tion abundances per sample per OTU. Subsequently, the data were analyzed by the STAMP (Statistical Analysis 
of Metagenomic Profiles) software package v. 2.1.377 to evaluate biologically meaningful differences between 
rhizosphere-associated Actinobacteria and the total bacterial community. Statistical inferences were performed 
by G-test (w/Yates) + Fisher’s, DP method: Asymptotic-CC 0.95 and p-value > 0.05 filter.
Isolation, culturing and identification of actinobacteria from rhizosphere. A pool of rhizosphere 
samples (0.25 g of each sample for three collected points; n = 9) was serially diluted  (10–4,  10–5 and  10–6) in saline 
solution (NaCl 0.85%), and aliquots of 100 μL were plated on Starch Casein Agar (SCA)78, Humic Acid-Vitamin 
Agar (HVA)79 and Yeast Extract Malt Extract Agar (YEME)80. All media were supplemented with cycloheximide 
and nystatin (25 μg/mL) and incubated at 16 °C for 6 weeks. Isolates from the Deschampsia antarctica rhizos-
phere with the typical morphology of Actinobacteria colonies were taken from the selective isolation plates. The 
pure cultures obtained by repeated streaking were maintained on Glucose Yeast Extract Agar (GYEA) at 4 °C 
and as mixtures of mycelial fragments and spores in 20% glycerol (v/v) at − 80 °C.
Genomic DNA extraction, PCR amplification and sequencing methods were performed according to pro-
cedures adopted in Souza et al. (2017)34. The 16S rRNA consensus contigs were obtained using PhredPhrap/
Consed81 and were aligned by ClustalW against nearest corresponding sequences using  EzBioCloud82 and MEGA 
7.042. Phylogenetic trees were inferred using the neighbour-joining83 tree-making algorithm drawn from the 
MEGA 7.0 package. Topologies of the resultant trees were evaluated by bootstrap  analysis84 based upon 1,000 
replicates.
cultivation, extraction, and isolation of bioactive compounds. The metabolites of Streptomyces 
sp. CMAA 1527 and Streptomyces sp. CMAA 1653 were obtained by growing cultures in Potato Dextrose Broth 
on a rotating shaker (180 rpm, 16 °C) for 10 days. After growth, the mycelium was separated by centrifugation 
(7,000 rpm, 15 min, room temperature) followed by filtration (0.22 μm filter membrane). Each liquid culture 
medium was extracted with ethyl acetate (1:3 v/v), and the organic phase was evaporated to dryness under 
vacuum (Büchi Waterbath B-480). From each crude extract, at least three aliquots were separated, and two 
of them were subjected to antifungal (oomycete Phytium aphanidermatum CMAA  243T) and antiproliferative 
(human tumour and non-tumour cell lines) evaluations. Aliquots of each crude extract (650 mg) were fraction-
ated by semipreparative HPLC on a Shimadzu LC system (Shimadzu, Kyoto, Japan) equipped with a CBM-20A 
controller, an LC-6AD pump, a DGU-20A5 degasser, and an SPD-20A UV–vis detector. The chromatographic 
separation was carried out using a  C18 Zorbax Eclipse XDB column (250 × 9.4 mm, 5 μm; Agilent), and the 
mobile phase used was composed of 0.1% formic acid as system A and acetonitrile as system B. The gradient 
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elution programme was 0—40 min from 30 to 100% of system B at a flow rate of 4 mL/min. The chromatograms 
were monitored using wavelengths at 320 and 500 nm.
Screening of bioactive strains. Antifungal activity. Bioactive strains were screened as described by San-
tos and Melo (2016)63, using Pythium. aphanidermatum CMAA  243T as a model organism. This bioassay was 
carried out as a primary screening for antitumour compounds from microorganisms. The antagonism assay was 
performed using sterile disc paper (0.5 cm diameter), crude extract solubilized in ethyl acetate (1 mg/mL) and 
potato dextrose agar medium. The plates were incubated at 28 °C for 24 h and evaluated according to the size of 
the inhibition zone, such as pronounced (+++), moderate (++), reduced (+) or absent (−).
Antiproliferative activity. The antiproliferative activity was investigated against a panel of human tumours 
[glioblastoma (U251), mamarian adenocarcinoma (MCF-7), ovarian multi-drug resistant adenocarcinoma 
(NCI/ADR-RES), large cell carcinoma of lung (NCI-H460), adenocarcinoma of kidney (786-0), ovarian adeno-
carcinoma (OVACAR-03), colon adenocarcinoma (HT-29) and chronic myeloid leukaemia (K-562)] and non-
tumour (HaCat, immortalized keratinocytes) cell lines growing in complete medium [RPMI 1640 supplemented 
with 5% foetal bovine serum and 1% penicillin/streptomycin mixture (1,000 UI:1,000 μg/mL)] at 37 °C and 5% 
 CO2 in a humidified atmosphere. Human tumour and the human non-tumoural cell lines were provided by the 
Frederick Cancer Research & Development Center (National Cancer Institute, Frederick, MD, USA), and Dr. 
Ricardo Della Colleta (University of Campinas).
The in vitro assay was performed as described by Monks et al. (1991)85. First, all extracts were screened 
against three tumour cell lines (U251, MCF-7 and NCI-H460). Then, the most promising extracts were evaluated 
against the complete panel. For both experiments, each extract was solubilized in dimethyl sulfoxide (100 mg/
mL) followed by serial dilution in complete medium affording the final concentrations (0.25, 2.5, 25 and 250 μg/
mL). Doxorubicin was used as a positive control at final concentrations of 0.025, 0.25, 2.5 and 25 μg/mL and was 
diluted following the same protocol.
Each cell line was grown in 96-well plates (100 μL cells/well) for 24 h and exposed for to the extracts, doxo-
rubicin (positive control) or complete medium (negative control) for 48 h. Before  (T0 plate) and after  (T1 plates) 
sample addition, cells were fixed with 50% trichloroacetic acid dyed with sulforhodamine B 0.4% in acetic acid 
0.1%, and colorimetric evaluation was recorded at 540 nm. The difference in absorbance between the untreated 
cells before  (T0 plate) and after  (T1 plates) sample addition represented 100% cell proliferation. Negative values 
represented a reduction in the cell population related to the  T0 plate. The cell proliferation data were analysed 
using Origin 8.0 software (OriginLab Corporation) using sigmoidal regression to calculate the TGI and  GI50 
values (sample concentrations required total cell growth inhibition or to elicit 50% of cell death, respectively).
Lc–MS analysis. The compounds present in the bioactive fractions were analysed using a Waters ACQUITY 
UPLC H-Class system coupled to the Xevo TQ-S tandem quadrupole (Waters Corporation, Milford, MA, USA) 
mass spectrometer with a Z-spray source operating in the positive mode and to the diode arrangement detec-
tor (DAD) from 220 to 600 nm, according to Crevelin et al. (2014)31. The samples were solubilized in MeOH 
and injected (5 µL) into a Zorbax Eclipse XDB-C18 column (150 × 4.6 mm, 3.5 µm particle size—Agilent, Santa 
Clara, CA, USA); the mobile phase used for gradient elution consisted of 0.1% formic acid as system A and ace-
tonitrile with 0.1% formic acid as system B. The flow rate was 0.5 mL/min, and the gradient elution programme 
started with 30% B, increased to 90% B in the following 25 min, remained at 90% B for 5 min, and returned to 
the initial condition within the following 5 min. The source and operating parameters were optimized as follows: 
capillary voltage, 3.2 kV; cone voltage, 40 V; source offset, 60 V; Z-spray source temperature, 150 °C; desolvation 
temperature  (N2), 350 °C; desolvation gas flow, 800 L/h (mass range from m/z 150 − 1,200).
High‑resolution mass spectrometry analysis. The exact mass of the compounds present in the bioac-
tive fractions was determined by high-resolution mass spectrometry (HRESIMS)31,86 on a mass spectrometer 
microTOFII-ESI-Q-TOF (Bruker Daltonics, Billerica, MA, USA) employing an infusion pump (Kd Scientific, 
Holliston, MA, USA) at a flow rate of 100 µL/min. The voltage of the capillary was 3,500 V, and the voltage of 
the end plate was − 400 V in positive ionization mode. The source and operating parameters were optimized as 
follows: drying gas temperature  (N2), 250 °C; a flow rate of 4 mL/min and a pressure of 0.4 bar. The tandem mass 
spectrometry experiments (MS/MS) with collision-induced dissociation were carried out using  N2 as the colli-
sion gas on the selected precursor ion at collision energy values ranging from 10 to 50 eV. For internal calibra-
tion, a solution of sodium trifluoroacetic acid (Na-TFA) at a concentration of 1 mg/mL was used. Data acquisi-
tion and analysis were performed using Compass Data Analysis 4.1 software (Bruker Daltonics Corporation).
nMR analysis. Nuclear magnetic resonance (NMR) measurements were carried out on a Bruker DRX 500 
spectrometer (Bruker Daltonics Corporation) operating at 500 MHz for 1H and 125 MHz for 13C (δ in parts 
per million relative to Me4Si, J in Hertz). The isolated sample (5 mg) was dissolved in deuterated chloroform 
 (CDCl3, Sigma-Aldrich) and analysed by 1D and 2D NMR using a Shigemi 5 mm NMR microtube, as described 
in Crevelin et al. (2013)86.
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